NCT03790774 is a NA clinical trial of Neurofeedback in Alzheimer Disease, sponsored by Oregon Health and Science University.

Who is sponsoring NCT03790774?

NCT03790774 is sponsored by Oregon Health and Science University.

What drugs are being tested in NCT03790774?

Interventions in NCT03790774: Neurofeedback.

What condition does NCT03790774 study?

NCT03790774 studies Alzheimer Disease.

Is NCT03790774 still recruiting?

NCT03790774 is currently terminated. Last updated 3 March 2021.

Last reviewed 2021-03-03 · How we verify

NCT03790774

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurofeedback in Alzheimer's Disease

Terminated NA Last updated 3 March 2021

What this trial tests

NA trial testing Neurofeedback in Alzheimer Disease in 5 participants. Terminated before completion.

Timeline

6 June 2019

Primary endpoint
1 June 2020

1 August 2020

Quick facts

Lead sponsor	Oregon Health and Science University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	5
Start date	6 June 2019
Primary completion	1 June 2020
Estimated completion	1 August 2020
Sites	1 location across United States

Drugs / interventions tested

Neurofeedback

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Oregon Health and Science University

Who can join

Adults 50 to 100, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate behavioral and electrophysiological changes in a sample of adults with possible or probable Alzheimer's disease (AD), before and after undergoing training using a brain-computer interface (BCI) system with neurofeedback based on electroencephalography (EEG). Participants will repeatedly complete a letter viewing task and receive visual and auditory cues about their brainwaves. The study team hypothesizes that exposure to this EEG-based biofeedback intervention (neurofeedback) will result in a reduction of theta activity (brainwaves in the range of 4-8 Hz). The study team also predicts that exposure to the neurofeedback intervention will result in increased performance on reading, attention, and working memory tasks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Brain-Computer Interfaces in Neurorecovery and Neurorehabilitation.
Young MJ, Lin DJ, Hochberg LR. · · 2021 · cited 35× · PMID 33742433 · DOI 10.1055/s-0041-1725137
Methodology and preliminary data on feasibility of a neurofeedback protocol to improve visual attention to letters in mild Alzheimer's disease.
Galvin-McLaughlin D, Klee D, Memmott T, Peters B, et al · · 2022 · cited 7× · PMID 35754975 · DOI 10.1016/j.conctc.2022.100950
Methodology and Preliminary Data on Feasibility of a Neurofeedback Protocol to Improve Visual Attention to Letters in Mild Alzheimer's Disease
Galvin-McLaughlin D, Klee D, Memmott T, Peters B, et al · · 2022 · DOI 10.2139/ssrn.4061360

Verify or expand the search:

Other trials of Neurofeedback

Trials testing the same drug.

NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT06587919 — Improving Dysregulated Neural Networks With EEG-neurofeedback · NA · enrolling by invitation
NCT06240299 — Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR) · NA · recruiting
NCT06188910 — Neurofeedback and Nomophobia in Young Adults · NA · completed
NCT06557525 — Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER) · Phase 1, PHASE2 · recruiting

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Oregon Health and Science University trials

Trials by the same sponsor.

NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03790774 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
Last refreshed: 3 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03790774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing